AACE/ACE disease state clinical review: Medical management of cushing disease

Amir H. Hamrahian, Kevin C J Yuen, Andrew R. Hoffman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objective: To review available medical therapies for patients with Cushing disease and to provide a roadmap for their use in clinical practice.Methods: PubMed searches were performed to identify all of the available published data on medical management of Cushing disease.Results: Medical therapy is usually not the first-line treatment for patients with Cushing disease but may be used to improve clinical manifestations of Cushing disease in patients who are not suitable candidates for surgery, following unsuccessful surgery or recurrence, or as a "bridge therapy" in those who have undergone radiotherapy. Medical therapy may also be used in preoperative preparation of patients with severe disease. Current available medical options for patients with Cushing disease include centrally acting agents, steroidogenesis inhibitors, and a glucocorticoid receptor antagonists. At present, there are no head-to-head studies comparing the efficacy, tolerability, and safety of different U.S. Food and Drug Administration (FDA)- and non-FDA-approved drugs in patients with Cushing disease. With the initiation of new studies and the completion of ongoing clinical trials, the number of FDA-approved drugs for medical treatment of Cushing disease is expected to increase.Conclusion: Medical therapy has an important adjunctive role in the management of patients with Cushing disease. The decision to initiate medical treatment depends on many factors, including patient characteristics and preference. Long-term studies are needed to better define the clinical efficacy, safety, and tolerability of medical treatment of Cushing disease, including the role of combination therapies.

Original languageEnglish (US)
Pages (from-to)746-757
Number of pages12
JournalEndocrine Practice
Volume20
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Pituitary ACTH Hypersecretion
Therapeutics
United States Food and Drug Administration
Pharmaceutical Preparations
Safety
Patient Preference
Glucocorticoid Receptors
PubMed
Radiotherapy
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

AACE/ACE disease state clinical review : Medical management of cushing disease. / Hamrahian, Amir H.; Yuen, Kevin C J; Hoffman, Andrew R.

In: Endocrine Practice, Vol. 20, No. 7, 01.07.2014, p. 746-757.

Research output: Contribution to journalArticle

Hamrahian, Amir H. ; Yuen, Kevin C J ; Hoffman, Andrew R. / AACE/ACE disease state clinical review : Medical management of cushing disease. In: Endocrine Practice. 2014 ; Vol. 20, No. 7. pp. 746-757.
@article{3e4024b9861f4b74a725bcbe94cbe02c,
title = "AACE/ACE disease state clinical review: Medical management of cushing disease",
abstract = "Objective: To review available medical therapies for patients with Cushing disease and to provide a roadmap for their use in clinical practice.Methods: PubMed searches were performed to identify all of the available published data on medical management of Cushing disease.Results: Medical therapy is usually not the first-line treatment for patients with Cushing disease but may be used to improve clinical manifestations of Cushing disease in patients who are not suitable candidates for surgery, following unsuccessful surgery or recurrence, or as a {"}bridge therapy{"} in those who have undergone radiotherapy. Medical therapy may also be used in preoperative preparation of patients with severe disease. Current available medical options for patients with Cushing disease include centrally acting agents, steroidogenesis inhibitors, and a glucocorticoid receptor antagonists. At present, there are no head-to-head studies comparing the efficacy, tolerability, and safety of different U.S. Food and Drug Administration (FDA)- and non-FDA-approved drugs in patients with Cushing disease. With the initiation of new studies and the completion of ongoing clinical trials, the number of FDA-approved drugs for medical treatment of Cushing disease is expected to increase.Conclusion: Medical therapy has an important adjunctive role in the management of patients with Cushing disease. The decision to initiate medical treatment depends on many factors, including patient characteristics and preference. Long-term studies are needed to better define the clinical efficacy, safety, and tolerability of medical treatment of Cushing disease, including the role of combination therapies.",
author = "Hamrahian, {Amir H.} and Yuen, {Kevin C J} and Hoffman, {Andrew R.}",
year = "2014",
month = "7",
day = "1",
doi = "10.4158/EP14147.RA",
language = "English (US)",
volume = "20",
pages = "746--757",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "7",

}

TY - JOUR

T1 - AACE/ACE disease state clinical review

T2 - Medical management of cushing disease

AU - Hamrahian, Amir H.

AU - Yuen, Kevin C J

AU - Hoffman, Andrew R.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Objective: To review available medical therapies for patients with Cushing disease and to provide a roadmap for their use in clinical practice.Methods: PubMed searches were performed to identify all of the available published data on medical management of Cushing disease.Results: Medical therapy is usually not the first-line treatment for patients with Cushing disease but may be used to improve clinical manifestations of Cushing disease in patients who are not suitable candidates for surgery, following unsuccessful surgery or recurrence, or as a "bridge therapy" in those who have undergone radiotherapy. Medical therapy may also be used in preoperative preparation of patients with severe disease. Current available medical options for patients with Cushing disease include centrally acting agents, steroidogenesis inhibitors, and a glucocorticoid receptor antagonists. At present, there are no head-to-head studies comparing the efficacy, tolerability, and safety of different U.S. Food and Drug Administration (FDA)- and non-FDA-approved drugs in patients with Cushing disease. With the initiation of new studies and the completion of ongoing clinical trials, the number of FDA-approved drugs for medical treatment of Cushing disease is expected to increase.Conclusion: Medical therapy has an important adjunctive role in the management of patients with Cushing disease. The decision to initiate medical treatment depends on many factors, including patient characteristics and preference. Long-term studies are needed to better define the clinical efficacy, safety, and tolerability of medical treatment of Cushing disease, including the role of combination therapies.

AB - Objective: To review available medical therapies for patients with Cushing disease and to provide a roadmap for their use in clinical practice.Methods: PubMed searches were performed to identify all of the available published data on medical management of Cushing disease.Results: Medical therapy is usually not the first-line treatment for patients with Cushing disease but may be used to improve clinical manifestations of Cushing disease in patients who are not suitable candidates for surgery, following unsuccessful surgery or recurrence, or as a "bridge therapy" in those who have undergone radiotherapy. Medical therapy may also be used in preoperative preparation of patients with severe disease. Current available medical options for patients with Cushing disease include centrally acting agents, steroidogenesis inhibitors, and a glucocorticoid receptor antagonists. At present, there are no head-to-head studies comparing the efficacy, tolerability, and safety of different U.S. Food and Drug Administration (FDA)- and non-FDA-approved drugs in patients with Cushing disease. With the initiation of new studies and the completion of ongoing clinical trials, the number of FDA-approved drugs for medical treatment of Cushing disease is expected to increase.Conclusion: Medical therapy has an important adjunctive role in the management of patients with Cushing disease. The decision to initiate medical treatment depends on many factors, including patient characteristics and preference. Long-term studies are needed to better define the clinical efficacy, safety, and tolerability of medical treatment of Cushing disease, including the role of combination therapies.

UR - http://www.scopus.com/inward/record.url?scp=84905007331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905007331&partnerID=8YFLogxK

U2 - 10.4158/EP14147.RA

DO - 10.4158/EP14147.RA

M3 - Article

AN - SCOPUS:84905007331

VL - 20

SP - 746

EP - 757

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 7

ER -